Arcturus Therapeutics and its Vietnam partner Vinbiocare will take ARCT-154, a next-generation Arcturus vaccine targeting SARS-CoV-2 variants of concern, into a Phase 1/2/3 trial. The companies will also establish a vaccine manufacturing centre in Vietnam....
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
A leader from the topical solutions centered CDMO discusses the differences between approaches by the FDA and EMA, and how to deal with them effectively.
The BiovitalsHF, from Biofourmis, is intended to augment decision-making in clinical environments, and to supplement traditional pharmaceutical therapies.
A recent check-in with several biopharma and CRO companies, conducted by Life Science Strategy Group, indicates adjustment to pandemic-related challenges.
The two pharma firms will partner to study the efficacy of Opdivo, paired with a SHP2 inhibitor, to treat non-small cell lung cancer with KRAS mutations.
A clinical trial logistics expert discusses specialized concerns involved in transporting cell and gene products and other personalized medicine items.
An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.
A new UK eLearning program is targeted at healthcare and academic professionals to support their learning on advanced therapy medicinal products (ATMPs).
The health data specialist and pharma firm are partnering on solutions around remote collection of digital data for detection and monitoring of treatments.
This month’s roundup of new excipients, manufacturing sites, partnerships, and other items includes news from DFE Pharma, Vetter, and other notable firms.
A leader from the artificial intelligence solutions firm discusses how advanced analytical tools can help researchers make the most of mountains of data.
A recent survey conducted by dosing technology firm found that the vast majority (85%) of patients think that personalized medicine stands to improve care.
The process management solutions firm says drug companies could use contract data to get a better handle on predicting demand and adjusting product output.
A recent study indicates patients taking the cholesterol-lowering drugs prior to COVID hospitalization are far less likely to die as a result of the virus.
The World Health Organization hopes to encourage the development of novel therapies for tuberculosis by spotlighting key clinical study characteristics.
The oncology-centered analytics firm will work with the DC-area healthcare provider to delve into discovery and development of novel cancer treatments.
Eli Lilly and Company and Banner Alzheimer’s Institute have announced a strategic research collaboration as part of the planned Phase 3 study for donanemab in participants at risk from cognitive and functional decline related to Alzheimer’s disease.
The past several days have seen a relatively large number of industry acqusitions, with Lilly, Phillip Morris, WCG, CTI and others making notable buys.
A representative from the medication management solutions company suggests patient behavior data can be used to improve adherence to trial drug regimens.
A leader from the clinical tech consultancy shares advice on how to employ training to help keep up with the rapidly evolving field of data management.
The two companies will work together to come up with solutions that use machine learning and artificial intelligence to help accelerate innovation in R&D.
According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.
A leader from life-sciences IT consultancy Daelight Solutions shares how the clinical trial data landscape has changed and offers advice on how to keep up.
US President Joe Biden singled out the pharmaceutical industry in his recently issued Executive Order on Promoting Competition in the American Economy.
Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiThera’s COVID-19 vaccine candidate, according to Phase 2 preliminary data.
The agency’s effort to fight the deadly disease now includes taps the pharma company’s testing tools to help speed up diagnosis and grow treatment access.
Acting US FDA commissioner, Janet Woodcock, has called for an independent federal review of interactions between officials at her agency and representatives of Biogen, prior to the recent approval of the pharma company’s treatment for Alzheimer’s disease....
During the Rare/Orphan Diseases, Special Patient Population webinar, a group of industry experts discussed challenges and opportunities faced in the field.
A leader from IQVIA suggests what to look for when seeking ways to automate drug safety processes, while maintaining security and customer satisfaction.
The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.
This month’s news on hires, promotions, acquisitions, and expansions includes items about Javara, Elligo, Lonza, Yourway, Medable, and other notable firms.
The two organizations have joined to create the Advocacy Exchange, a virtual platform designed to bring together patients, advocates and industry leader.
A leader from the trial management specialist says sites and sponsors prepare for International Council for Harmonization guideline changes on the horizon.
Thanks in part to the recent completion of an $8m investment, 2020 On-site plans to expand its services, including the mobile support of vision research.
The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.
The trial solutions firm is working with Children’s Oncology Group to expand in-home research and care options for investigational immune-oncology therapy.
The company’s ryze technology combines a clinical MDR and study automation platform, designed to accelerate and optimize design and execution of trials.
As the industry begins coming out of the COVID-19 pandemic, experts advise keeping an eye on growth and partnership opportunities in the US pharma market.
The survey, conducted by Ai-powered study matching company TrialJectory, indicates more patients than ever are interested in clinical trial participation post-pandemic.
The project will use the artificial intelligence specialist’s cell-centered models and deconvolutions to gain insights for each individual asthma endotype.
The annual event (scheduled July 12-16 online) will feature educational sessions, presentations, and networking opportunities for drug manufacturing pros.
